


1st Mayo Clinic - Vall d'Hebron

NEPHROLOGY UPDATE



Barcelona - September 5th-6th, 2025

Directors:



Oriol Bestard

Hospital Universitari Vall d'Hebron. Barcelona



María José Soler

Hospital Universitari Vall d'Hebron. Barcelona



Sandra Herrmann

Mayo Clinic. Rochester, USA



Fernando Fervenza

Mayo Clinic. Rochester, USA



Venue___ Auditorium. Vall d'Hebron Institut de Recerca
Passeig de la Vall d'Hebron, 119

Friday, September 5th

08:40 Opening

09:00 Pregnancy & CKD

Chairs:

Vesna Garovic. *Mayo Clinic. Rochester, USA*

Sheila Bermejo. *Hospital Universitari Vall d'Hebron. Barcelona*

Blood pressure goals and treatments in pregnancy

Andrea Kattah. *Mayo Clinic. Rochester, USA*

Footprint of preeclampsia in Kidney and Heart

Vesna Garovic. *Mayo Clinic. Rochester, USA*

10:00 Guidelines update in polycystic and Alport diseases

Chairs:

Laia Sans. *Hospital Universitari Vall d'Hebron. Barcelona*

Mercedes López. *Hospital Universitari Vall d'Hebron. Barcelona*

KDIGO 2025 autosomal dominant polycystic kidney disease guideline

Vicente Torres. *Mayo Clinic. Rochester, USA*

ERKNet, ERA and ESPN Alport syndrome guideline

Mónica Furlano. *Fundació Puigvert. Barcelona*

11:00 Coffee Break

11:20 New treatments for Chronic kidney disease

Chairs:

Fernando Fervenza. *Mayo Clinic. Rochester, USA*

María A. Azancot. *Hospital Universitari Vall d'Hebron. Barcelona*

When to start SGLT2i in patients with Glomerular disease

María José Soler. *Hospital Universitari Vall d'Hebron. Barcelona*

GLP1 in CKD, where are we now?

Clara García Carro. *Hospital Clínico San Carlos. Madrid*

Targeting aldosterone as a key to transforming cardiorenal care: present & future

Sara Núñez. *Hospital Universitari Vall d'Hebron. Barcelona*

12:40 CAR-T Cell therapy and AKI

Chairs:

Sheila Bermejo. *Hospital Universitari Vall d'Hebron. Barcelona*

Clara García Carro. *Hospital Clínico San Carlos. Madrid*

CAR-T & AKI experience at Mayo Clinic

Sandra Herrmann. *Mayo Clinic. Rochester, USA*

CAR-T & AKI experience at Vall d'Hebron

Juan León. *Hospital Universitari Vall d'Hebron. Barcelona*

13:30 Light Lunch

14:30 Personalized Kidney transplantation

Chairs:

María Meneghini. *Hospital Universitari Vall d'Hebron. Barcelona*

Carrie A. Schinstock. *Mayo Clinic. Rochester, USA*

Update on latest STAR guidelines. Controversies and new challenges

Carrie A. Schinstock. *Mayo Clinic. Rochester, USA*

New desensitization targets in Highly Sensitized Patients Awaiting Kidney Transplant

Oriol Bestard. *Hospital Universitari Vall d'Hebron. Barcelona*

To maintain or not the immunosuppression after kidney allograft failure?

Mark Stegall. *Mayo Clinic. Rochester, USA*

15:40 Improving Living donor Kidney transplant outcomes (Clinical Cases)

Chairs:

Joana Sellarés. *Hospital Universitari Vall d'Hebron. Barcelona*

Mark Stegall. *Mayo Clinic. Rochester, USA*

How to predict Living kidney donor transplant outcomes

Naim Issa. *Mayo Clinic. Rochester, USA*

Pushing the limits in Living kidney donor transplantation

Francesc Moreso. *Hospital Universitari Vall d'Hebron. Barcelona*

Saturday, September 6th

09:00 Update in glomerular diseases

Chairs:

Marina López. *Hospital Universitari Vall d'Hebron. Barcelona*

Ladan Zand. *Mayo Clinic. Rochester, USA*

Monoclonal gammopathy and the kidney

Ladan Zand. *Mayo Clinic. Rochester, USA*

New target antigens in Membranous Nephropathy (Online)

Sanjeev Sethi. *Mayo Clinic. Rochester, USA*

Targeting B-Cell in ANCA vasculitis

Ulrich Specks. *Mayo Clinic. Rochester, USA*

A personal approach to the treatment of IgA nephropathy

Fernando Fervenza. *Mayo Clinic. Rochester, USA*

10:45 Coffe Break

11:15 Lights in the shadows of Lupus Nephritis

Chairs:

Oriol Bestard. *Hospital Universitari Vall d'Hebron. Barcelona*

Irene Agraz. *Hospital Universitari Vall d'Hebron. Barcelona*

Lupus Nephritis: redefining treatment goals

Fernando Fervenza. *Mayo Clinic. Rochester, USA*

New treatments in Lupus Nephritis?

Ali Duarte. *Mayo Clinic. Rochester, USA*

12:15 Complement Treatment & the kidney

Chairs:

María José Soler. *Hospital Universitari Vall d'Hebron. Barcelona*

Sandra Herrmann. *Mayo Clinic. Rochester, USA*

Ex vivo C5b-9 Deposition and complement inhibition in glomerular diseases

Conxita Jacobs. *Hospital Universitari Vall d'Hebron. Barcelona*

C3 and complement inhibition

Fernando Caravaca. *Hospital Universitario 12 de Octubre. Madrid*

Thrombotic microangiopathy and complement inhibition

Miquel Blasco. *Hospital Clínic. Barcelona*

13:30 Closing Remarks

Oriol Bestard. *Hospital Universitari Vall d'Hebron. Barcelona*

María José Soler. *Hospital Universitari Vall d'Hebron. Barcelona*

Sandra Herrmann. *Mayo Clinic. Rochester, USA*

Fernando Fervenza. *Mayo Clinic. Rochester, USA*

Organized by _____



1st Mayo Clinic - Vall d'Hebron

NEPHROLOGY UPDATE



Barcelona - September 5th-6th, 2025

Scientific Endorsement _____



*Las opiniones expresadas por los autores
no reflejan necesariamente la posición de la S.E.N.*

Colaborating Entities _____



Technical Secretariat _____ MUNDICONGRES, S.L.

 mundicongres@mundicongres.com  91 411 6996